(Q84612094)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20668480%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

Targeted therapies: Denileukin diftitox--a step towards a 'magic bullet' for CTCL (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20668480%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

Marshall E Kadin

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20668480%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Eric C Vonderheid

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20668480%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

1 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20668480%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

8 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20668480%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20668480%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20668480%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

430-432

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20668480%20AND%20SRC:MED&resulttype=core&format=json

Denileukin diftitox: a novel immunotoxin

8 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.105

Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.105

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.105

Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.105

CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.105

FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.105

A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.105

Stress-induced enhancement of skin immune function: A role for gamma interferon

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.105

Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.105

10.1038/NRCLINONC.2010.105

31 March 2020

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20668480%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference